Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 15, 2020
Daily News
October 15, 2020
- Japan Sees Improved LHRH Agonist Supply as Leuprorelin Output Rises; Shipment Curbs for Substitutes Lifted
October 15, 2020
- PMDA Gets Nearly 10 Requests for Free COVID-19 Vaccine Consultations in 2 Weeks
October 15, 2020
- Remicade Biosimilars Expand Labels into Ankylosing Spondylitis
October 15, 2020
- Takeda Links Arms with Accenture, AWS to Accelerate Digital Transformation
October 15, 2020
- Cefiderocol Demonstrated Non-Inferiority to Meropenem in Global PIII: Shionogi
October 15, 2020
- LEO Pharma, Hokkaido Univ. Pair Up to Identify Therapeutic Targets in Leukoplakia, Alopecia Areata
October 15, 2020
- MHLW to Make “Comprehensive Decision” on Off-Year Drug Pricing Plan: Minister
October 15, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…